Company Overview
SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.
Why Investors Should Care
Revenue has grown at a 58.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of $2.20M (-34.7% YoY); net profit $-3.82M.
- Trailing 12 Months Year-on-year growth — revenue -7.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 58.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 58.11% |
| 1 Year: | -7.60% |
Stock Price Performance
| 1 Year: | -74.49% |
| 6 Months: | -71.83% |
| 3 Months: | -74.06% |
| 1 Month: | -1.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 58.1% over 5 years.
CONS
- Trading 79.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLBT SL Science Holding Limited PHARMA | 2.62 | -262.00 | $1.47B | 0.00% | - | - | 58.11% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 878.97K | 3.36M | 2.20M |
| Cost of Revenue | 140.96K | 1.43M | 1.42M |
| Gross Profit | 738.01K | 1.93M | 775.06K |
| Operating Expenses | 641.18K | 3.13M | 4.61M |
| Operating Income | 96.83K | -1.20M | -3.84M |
| EBITDA | 134.02K | -1.15M | -3.74M |
| Interest Expense | - | - | - |
| Pretax Income | 532.87K | -1.13M | -3.82M |
| Tax Provision | 133.84K | 57.63K | -4 |
| Net Income | 399.04K | -1.19M | -3.82M |
| Diluted EPS | 0.00 | -0.00 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 4.24M | 5.93M | 2.82M |
| Current Assets | 3.49M | 5.86M | 1.43M |
| Cash & Equivalents | 276.85K | 3.68M | 1.26M |
| Inventory | 1.48M | 1.36M | 0 |
| Receivables | 26.88K | 0 | - |
| Total Liabilities | 668.07K | 204.90K | 533.28K |
| Current Liabilities | 183.03K | 69.20K | 468.54K |
| Long Term Debt | - | - | - |
| Total Debt | 550.06K | 0 | 213.41K |
| Total Equity | 3.57M | 5.73M | 2.28M |
| Shares Outstanding | 560.76M | 560.76M | 560.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -2.45M | 280.16K | -1.91M |
| Investing Cash Flow | -182.98K | 123.28K | -319.69K |
| Financing Cash Flow | 2.86M | 3.07M | -879.14K |
| Capital Expenditure | -182.98K | -7.97K | -319.69K |
| Free Cash Flow | -2.64M | 272.19K | -2.23M |
| Net Change in Cash | 223.65K | 3.47M | -3.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 84.0% | 57.5% | 35.3% |
| Operating Margin % | 11.0% | -35.6% | -174.6% |
| Net Margin % | 45.4% | -35.4% | -173.8% |
| ROE % | 11.2% | -20.8% | -167.2% |
| ROCE % | 2.4% | -20.4% | -163.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.03% | 193.40K | $332.65K |
| 2 | L1 Global Manager Pty Ltd | 0.03% | 150.00K | $258.00K |
| 3 | RiverNorth Capital Management, LLC | 0.02% | 130.00K | $223.60K |
| 4 | SkyView Investment Advisors, LLC | 0.01% | 42.04K | $72.31K |
| 5 | Lynx Capital Group Ltd /adv | - | 17.10K | $29.41K |
| 6 | UBS Group AG | - | 12.52K | $21.52K |
| 7 | Heights Capital Management, Inc | - | 20.00K | $34.40K |
| 8 | Jane Street Group, LLC | - | 14.54K | $25.01K |
| 9 | Osaic Holdings Inc. | - | 286 | $491 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLBT
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBka2Z6R2FhdEh0bEpVREVtaHBmeGp2eVBla3RpTE5EeU1LT0hGQmNtMTNnbzU2VzJJaDJLVUpRaklqMS1XTW1ZWUdYWWNadWFu?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNRlFfeXAzMjk3bDR6QURVQjRKYXlVU2lyWGxiZHBHWTlnOTVVSFV4NklBRHNTak1QUFE4VzVtaFNuTlR4RlFKYmppdVZjdVJIa2E3bk5mcjQ2ZmJobGJybm0tYVBvSWdQUGJReWRoNjRiZFZwZ1BBbFlkczlDSDNLbnoxVmFLMW9WM2FmMn…
SL Science’s 2025 revenue fell 35% as R&D spending held at $2.07M - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNLV9vb0s2MDZGZW5Zdzh4R1QxQS1rZXlJNW5GRk1xVk9Qd3EwdXVpNE9iYXc2WG9yRTVvcHhxRGVZcVVENVptLTZ3TU9RaUdCV3hoTU5vN3k0ZHBBN1hNUWZ2WDQ1d05QdDBaMV9vY1RwWHd5VndFay1xbzNveDNSUUx6QXhlY09BZzJpaF…
SL Science Holding Limited Ordinary Shares (NASDAQ: SLBT) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE95SEpiOXA5ZGlaYkpJdDgtanlVb0dDZ3hDUGJ3NkxGYUprTXhQbkU5dmg5S0YzMXM3Y1RXREc3UEhKZDViZDRDZlpsbllDMGt6T0JDU1ln?oc=5" target="_blank">SL Science Holding Limited Ordinary Shares (NASDAQ:…
SLBT Stock Whipsaws As Volatility Attracts Active Traders - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNR3V0MlFFTEpncm5hdTFyOHVPOHpFeGRIN29vYXZyVy1nRzhTVlJrUGlHckNVbV94NDU2TnhURzlBVGVlOVJmX1FiLUh0c3R6T19HUUUzamxvYXAtVHUzUXFHUFp5aHk2ZGtjd1ZOQ0xTdEhDR2lYd0hUQzZrTVdka2I4cEZldw?oc=5" t…
SL Science Holding Limited to Begin Trading on Nasdaq as "SLBT" Following Successful Business Combination with Horizon Space Acquisition II Corp. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxOTWZvWXV5RXR6TllGbzdQRnlVeTRfdjhrY3ZZQV9SeDktcFFsSzdjV0tKRml4QUQ0NEJOOWhsajdpV0hBMmhIVXdJYy10NmR6MHotWF9XOHlGRE9sSURXbUVoUU0tR1JSX2Z4U21JRHgtOE1PWEVTWmpKRVRkRnpjRVNWazIxcHhIei0zWl…
SLBT — Frequently Asked Questions
What is the current share price of SL Science Holding Limited (SLBT)?
As of 2026-09-19 21:16 PDT, SL Science Holding Limited (SLBT) trades at $2.62 on NasdaqGM. Its 52-week range is $2.60 to $12.81.
What is the market capitalisation of SLBT?
SL Science Holding Limited (SLBT) has a market capitalisation of $1.47B on NasdaqGM.
What is the P/E ratio of SLBT?
SLBT trades at a trailing price-to-earnings (P/E) ratio of -262.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.34.
Is SLBT a good stock to buy?
This page provides a data-driven analysis of SL Science Holding Limited (SLBT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.